Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 2 of 15

 
 

Grifols (NASDAQ:GRFS)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$10.30 (23.1% Upside)

About Grifols

Grifols logoGrifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. More about Grifols
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/17/2025JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$7.60 ➝ $10.30
2/12/2025Morgan StanleyInitiated CoverageOverweight
10/29/2024Berenberg BankUpgradeStrong-Buy
3/12/2024Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
12/5/2023JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$10.00 ➝ $10.50
8/29/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight
4/12/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/3/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight
2/16/2023BarclaysUpgradeUnderweight ➝ Equal Weight
2/6/2023AlphaValueUpgradeBuy
 

From Our Partners